United States · Markets & Finance · Investor's Business Daily

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Published by Investor's Business Daily · United States 12 h ago

Eli Lilly (LLY) already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market. The new contender, EloraTZP, helped patients with type 2…

Read the full article on Investor's Business Daily Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)

Also worth reading

Cointelegraph

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

OilPrice.com

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug

Share

Also worth reading

MetaMask exits Lido validators as it investigates security incident

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Gemini 4 Is Here, and Google’s Flagship Tops All Other AI Models on Cybersecurity

EU Gas Crunch Forces Rethink of Methane Rules